US 12,433,850 B2
Enhanced delivery epinephrine and prodrug compositions
Alexander Mark Schobel, Whitehouse Station, NJ (US); Stephanie Marie Varjan, Oradell, NJ (US); and Stephen Paul Wargacki, Annandale, NJ (US)
Assigned to Aquestive Therapeutics, Inc., Warren, NJ (US)
Filed by AQUESTIVE THERAPEUTICS, INC., Warren, NJ (US)
Filed on Sep. 27, 2018, as Appl. No. 16/143,821.
Application 16/143,821 is a continuation in part of application No. 15/791,249, filed on Oct. 23, 2017.
Application 15/791,249 is a continuation in part of application No. 15/717,859, filed on Sep. 27, 2017, abandoned.
Application 15/717,859 is a continuation in part of application No. 15/587,364, filed on May 4, 2017.
Claims priority of provisional application 62/331,996, filed on May 5, 2016.
Prior Publication US 2019/0022023 A1, Jan. 24, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/70 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 36/61 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01); A61K 47/44 (2017.01); A61P 9/02 (2006.01); A61P 9/04 (2006.01); A61P 9/06 (2006.01); A61P 27/06 (2006.01)
CPC A61K 9/7007 (2013.01) [A61K 9/006 (2013.01); A61K 31/137 (2013.01); A61K 36/61 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61K 47/44 (2013.01); A61P 9/02 (2018.01); A61P 9/04 (2018.01); A61P 9/06 (2018.01); A61P 27/06 (2018.01)] 39 Claims
 
1. A pharmaceutical composition for oral delivery, comprising:
an oral mucoadhesive polymeric matrix in a film that is orally dissolvable;
a pharmaceutically active component including epinephrine or its prodrug in the polymeric matrix; and
an adrenergic receptor interacter that creates increased blood flow or enables a flushing of the tissue to modify transmucosal uptake of the pharmaceutically active component thereof through a mucosal barrier by utilizing at least a paracellular transport route or mechanism, wherein the pharmaceutical composition is a film, the pharmaceutically active component being contained in the polymeric matrix of the film.